Edison Therapeutics

Edison Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of novel treatments for neurological and psychiatric disorders, with a primary focus on Alzheimer's disease. The company utilizes a sophisticated drug repurposing strategy to identify existing small molecule compounds with established safety profiles that can be redirected toward central nervous system (CNS) indications. Its lead program, ET-101, is currently being evaluated in Phase 2 clinical trials for the treatment of mild-to-moderate Alzheimer's disease. Founded by Dr. Jeffrey Cummings, a world-renowned expert in Alzheimer's research and clinical trial design, the company aims to accelerate the delivery of effective therapies by leveraging known pharmacology and existing clinical data. Edison Therapeutics is headquartered in Las Vegas, Nevada, and maintains strong ties to academic research institutions.